

# Pierre-Jean Lamy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5148169/publications.pdf>

Version: 2024-02-01

82  
papers

3,017  
citations

147801

31  
h-index

175258

52  
g-index

108  
all docs

108  
docs citations

108  
times ranked

5667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014, 20, 430-435.	30.7	582
2	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013, 6, 319-IN8.	3.7	143
3	HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 133-142.	7.7	109
4	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of <i>In situ</i> Carcinoma of the Breast in Younger Women. <i>Clinical Cancer Research</i> , 2009, 15, 4733-4741.	7.0	99
5	Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. <i>Lung Cancer</i> , 2000, 29, 197-203.	2.0	88
6	Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 131-138.	2.0	84
7	Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers. <i>Journal of Urology</i> , 2007, 178, 844-848.	0.4	81
8	Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. <i>Annals of Oncology</i> , 2015, 26, 908-914.	1.2	81
9	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
10	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. <i>Scientific Reports</i> , 2018, 8, 15931.	3.3	67
11	Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. <i>European Urology Focus</i> , 2018, 4, 790-803.	3.1	64
12	Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. <i>Breast Cancer Research</i> , 2011, 13, R15.	5.0	56
13	KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. <i>International Journal of Molecular Sciences</i> , 2011, 12, 3191-3204.	4.1	52
14	SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. <i>BMC Cancer</i> , 2013, 13, 351.	2.6	52
15	Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis. <i>Clinical Chemistry</i> , 2008, 54, 574-581.	3.2	50
16	Measles Virus Exploits Dendritic Cells to Suppress CD4+ T-Cell Proliferation via Expression of Surface Viral Glycoproteins Independently of T-Cell Trans-infection. <i>Cellular Immunology</i> , 2001, 214, 173-183.	3.0	49
17	Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 65-71.	2.5	49
18	Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. <i>Cancer Medicine</i> , 2017, 6, 2461-2470.	2.8	48

#	ARTICLE	IF	CITATIONS
19	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018, 119, 76-79.	6.4	48
20	BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. <i>BMC Cancer</i> , 2013, 13, 523.	2.6	44
21	Iron homeostasis and anemia markers in early breast cancer. <i>Clinica Chimica Acta</i> , 2014, 434, 34-40.	1.1	42
22	Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. <i>International Journal of Cancer</i> , 2013, 132, 1105-1113.	5.1	41
23	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , 2017, 78, 162-175.	1.4	39
24	Night work and prostate cancer risk: results from the EPICAP Study. <i>Occupational and Environmental Medicine</i> , 2018, 75, 573-581.	2.8	39
25	Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 709-717.	2.5	38
26	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. <i>Breast Cancer Research</i> , 2011, 13, R133.	5.0	37
27	Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1992-2000.	7.0	36
28	The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 146-157.	7.4	34
29	Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 366-373.	2.8	34
30	KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. <i>Modern Pathology</i> , 2012, 25, 731-739.	5.5	33
31	Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. <i>Oncotarget</i> , 2018, 9, 34485-34494.	1.8	33
32	Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0128836.	2.5	28
33	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	3.7	27
34	Serum HER2 extra-cellular domain, S100 $\beta$ and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 428.	2.6	26
35	Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. <i>Annals of Oncology</i> , 2016, 27, 1235-1241.	1.2	25
36	Serum protein signature may improve detection of ductal carcinoma in situ of the breast. <i>Oncogene</i> , 2010, 29, 550-560.	5.9	24

#	ARTICLE	IF	CITATIONS
37	Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1119-1126.	1.1	23
38	Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. <i>International Journal of Cancer</i> , 2016, 139, 2299-2311.	5.1	23
39	NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 3-12.	2.3	22
40	Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. <i>International Journal of Oncology</i> , 2013, 43, 1683-1690.	3.3	22
41	Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. <i>Cancers</i> , 2020, 12, 3002.	3.7	22
42	Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. <i>BMC Cancer</i> , 2014, 14, 106.	2.6	20
43	Analysis of the potential contribution of estrogen receptor (ER) $\beta$ in ER cytosolic assay of breast cancer. <i>International Journal of Cancer</i> , 2001, 95, 205-208.	5.1	19
44	Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 91, 430-433.	6.4	19
45	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.	2.6	19
46	Body mass index trajectories and prostate cancer risk: Results from the EPICAP study. <i>Cancer Medicine</i> , 2020, 9, 6421-6429.	2.8	19
47	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667.	2.5	17
48	Circadian genes and risk of prostate cancer: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2019, 145, 1745-1753.	5.1	17
49	Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA. <i>American Journal of Clinical Pathology</i> , 2007, 128, 404-413.	0.7	16
50	Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2020, 147, 3119-3129.	5.1	16
51	Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. <i>Future Oncology</i> , 2014, 10, 195-209.	2.4	15
52	Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?. <i>Future Oncology</i> , 2015, 11, 557-559.	2.4	15
53	Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 770.	2.6	15
54	Androgenic hormones and the excess male mortality observed in COVID-19 patients: new convergent data. <i>World Journal of Urology</i> , 2021, 39, 3121-3123.	2.2	15

#	ARTICLE	IF	CITATIONS
55	Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and 1833-41.	2.3	14
56	Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagnostic Pathology, 2012, 7, 13.	2.0	13
57	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	2.6	11
58	Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2âˆ’ pN0 early breast cancers. Breast Cancer Research and Treatment, 2017, 165, 611-621.	2.5	11
59	<sc>P</sc>rostatitis, other genitourinary infections and prostate cancer risk: <sc>I</sc>nfluence of nonâ€steroidal antiâ€inflammatory drugs? <sc>R</sc>esults from the <sc>EPICAP</sc> study. International Journal of Cancer, 2018, 143, 1644-1651.	5.1	11
60	Clinical Utility of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain Levels: Stop the Shilly-Shallyâ€”It Is Time for a Well-Designed, Large-Scale Prospective Study. Journal of Clinical Oncology, 2009, 27, e286-e287.	1.6	10
61	Serum Matrix Metalloproteinaseâ€7 is an independent prognostic biomarker in advanced bladder cancer. Clinical and Translational Medicine, 2014, 3, 31.	4.0	10
62	Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clinical Breast Cancer, 2018, 18, 144-149.	2.4	10
63	Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. Oncotarget, 2018, 9, 23661-23669.	1.8	8
64	KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1074-1075.	6.4	6
65	High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report. Annales De Biologie Clinique, 2016, 74, 490-494.	0.1	4
66	Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP). Journal of Occupational Medicine and Toxicology, 2022, 17, 5.	2.2	4
67	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. European Journal of Cancer, Supplement, 2012, 10, 120-127.	2.2	3
68	Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. Annales De Biologie Clinique, 2017, 75, 9-18.	0.1	3
69	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. Anticancer Research, 2018, 38, 2909-2914.	1.1	3
70	Impact de la TEP/TDM au 18F-FDG dans la prise en charge des patients atteints de cancer thyroÃ©dien diffÃ©renciÃ©. Medecine Nucleaire, 2010, 34, 78-87.	0.2	2
71	<i>TOP2A</i> Amplification in Breast Cancer in the Absence of That of <i>HER-2</i>: Myth or Reality?. Oncologist, 2012, 17, e60-e61.	3.7	2
72	Kinetics of HE4 and CA125 markers in metastatic ovarian cancer: The META4 study.. Journal of Clinical Oncology, 2017, 35, e17059-e17059.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Classification moléculaire des cancers du sein: utilité en clinique. <i>Medecine Nucleaire</i> , 2010, 34, 32-43.	0.2	1
74	Re: Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2013, 105, 149-149.	6.3	1
75	Relevance of total PSA and free PSA prescriptions. <i>Annales De Biologie Clinique</i> , 2018, 76, 659-663.	0.1	1
76	SERUM PRO-MATRIX METALLOPROTEINASE-7 (PRO-MMP-7) AS A PREDICTIVE MARKER FOR EARLY PROGRESSION AFTER NEPHRECTOMY IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2009, 181, 109-109.	0.4	0
77	Cancer de la prostate: les niveaux de preuve des biomarqueurs de la détection précoce. <i>Medecine Nucleaire</i> , 2014, 38, 14-17.	0.2	0
78	Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology. <i>Journal of Applied Biomedicine</i> , 2018, 16, 214-220.	1.7	0
79	Abstract 679: Retrospective evaluation of the BRCA1 - PARP pathway in breast cancer tissues. , 2012, , .		0
80	Comparison of prostate health index and PCA3 values in patients with clinical or biologic suspicion of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5055-5055.	1.6	0
81	Abstract P5-21-02: Final results of the VitaCal randomized phase III study evaluating the impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients. , 2015, , .		0
82	Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of Endopredict® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers. , 2020, , .		0